Juvenile Diabetes Research Foundation Limited Annual Report and Financial ststements 30 June 2021 Company Limil&d by Guarantee Registration Number 02071638 (England and wa￿S) Charity Regi8tralion Number 295716 (Englandl and SC040123 (Scotlandl Contents Reports Directors, ￿port Reference and administrative details 21 Independent auditor's report 23 Flnanclal Statements Consolidated stslement of financial activities 28 Balance sheets 29 Consolidated stslement of cash flows 30 Principal accounting policies 31 Notes lo the financial statements 36 Juvenile Diabetes Research Foundation Limited Dlrectors, report Year ended 30 June 2021 The Directors present their report, together with the audited financial statements of Juvenile Diabetes Research Foundation Limited I'the eharilable company'l, for the year ended 30 June 2021. This report has been prepared in accordance with Part 8 of the Charities Act 2011 and the Charities Accounts Iscotlandl Regulations 2006 las amended) and setves as the report of the D1￿ClorS for the purposes of the Companies Act 2006. The financial statements have been prepared in accordance with the accounting policies sel out on pages 31 to 35 and comply with the charitable company's Articles of Association, applicable laws and Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to eharilies preparing their accounts in aecordanee with the Financial Reporting Stsndard applicable in the United Kingdom and Republic of Ireland IFRS 1021, effective from accounting periods commencing 1 January 2015 or later. About JDRF: a global mlsslon to Cure type 1 dlabetes JDRF in the UK is proud to be a part of a global network of independent and coordinated organisalions working towards the same vision. There are JDRF affiliates in the USA, UK, Canada, Australia, Netherlands and Israel. JDRF'S intemalional Mission is to improve lives today and tomorrow by accelerating life- changing breakthroughs to cure, prevent and Ireal type 1 diabetes and its complications. Our mission in the UK JDRF'S vision is a world wilhoul type 1 diabetes. To achieve our mission of eradicating type 1 diabetes and its effects for people in the UK we". Drive research to cure, treat and prevent type 1 Accelerate access to type 1 treatment technologies and medicines Support people living with type 1 Through our international JDRF ne￿ork, our funding of UK researchers, our advocacy work with the NHS and the support we provide lo people with type 1, we know that we can push new boundaries and generate unprecedented progress in the next few years lo prevent, treat and ultimately find cures for type 1 diabetes. Juvenile Diabetes Research Foundation Limited Dlrectors, report Year ended 30 June 2021 Chair & CEO Foreword This year we marked the eentenary of the ground-breaking discovery of insulin. We've reflected back on this triumph of international research collaboration that has saved millions of lives, whilst focusing on the challenges and opportunities that will shape the future of type 1 diabetes research. This centenary year has been an exceptionally difficult one for people with type 1, due lo the ongoing Covid pandemic. As well as being at increased risk of adverse effects from Covid infection, our beneficiaries have been challenged by the disruption lo clinical servI￿s, on top of the intensive daily management that type 1 diabetes requires. Throughout the course of the last year we have built on our reputation as a trusted and reliable source of information and support for people with type 1. We have continued lo provide up-l￿date and clinically approved Covid information on ourwebsile and encouraged the uptake of Covid vaccinations amongst the type 1 community. Our information and support events have continued to engage people with type 1 in the virtual space. Despite the challenges, we have made real progress this year and pushed closer than ever to realising our commitment to finding transformational treatments and cures. The JDRF- funded immunotherapy leplizumab, which can delay type 1 diabetes by three years, may soon become the first li￿n￿d therapy lo modify the condition, potentially paving the way to cures. We have also influenced progress in widening access to technology for people with type 1 diabetes. The NHS announced a pilot scheme that could make the artificial pancreas la technological advance under-pinned by JDRF-funded research) available to people with type 1 across England, potentially as early as 2022. The artificial pancreas connects data from blood glucose monitors with insulin pumps through a complex algorithm to automatically adjust the dosage of insulin, lifting the burden of constant monitoring, improving healthy blood glucose lime in range levels and helping reduce risk of long-lerm he81th complications. Over the last year, we have made hard but appropriate decisions in response to the financial pressures that have been felt across the sector. We have steadfastly focused on optimum delivery of our mission while adapting lo a significant loss in our traditional fundraised income. We reduced all forms of direct expenditure other than research funding, advocacy and beneficiary support services and during the year reduced our total stsff team by 20 per￿n1 through redundancies and voluntsry allrilion. We placed a similar number of staff on fudough between April and November 2021. We are so grateful for the enduring loyalty of our supporters who continued lo fundraise for us in the most difficult of Circumstan￿$. In particular, we want to recognise the generosity of Steve and Sally Morgan who, through their charitable foundation, granted JDRF funding. This grant in turn secured matched funding from the Department for Digital, Cultu￿, Media and Sport, enabling us to compensate for the losses caused by the pandemic and achieve income this year of £6.4 million. This enabled us to increase our funding of research lo the highest level ever, both in absolute and proportionate terms. Juvenile Diabetes Research Foundation Limited Dlrectors, report Year ended 30 June 2021 Chair & CEO Foreword Icontinuedl FY21 has been a challenging year, but we have shown our resilience and ability to stay the course, providing much-needed support for people with type 1 who have been disproportionately affected by Covid-19. A hundred years after the discovery of insulin, we continue lo push towards our ultimate goal - a world without type 1 diabetes. David McTurk Karen Addinglon Chair CEO Juvenile Diabetes Research Foundation Limited Dlrectors, report Year ended 30 June 2021 OUR THREE YEAR STRATEGY: FY21-23 FY21 is the first year of JDRF'S three year FY21-23 strategy, which furthers our vision of a world wilhoul type 1 diabetes. The strategy embeds a greater focus on mission outcomes and organisalional effectiveness. Drive research to cure. treat and prevent type 1 We are commilled lo increasing funding for world-class international type 1 diabetes research, with UK research teams at the forefront, and building research communities across autoimmune conditions. Accelerate access to type 1 treatment technologies and medicines We are commilled lo working with key national decision makers to broaden access lo technology and Irealments, and involve people with type 1 in research, regulatory design, process and practice. Support people living with type 1 We are committed to building connected communities lo support people living with type 1 and being a trusted Sour￿ of infomialion. This report outlines our progress against the first year of this strategy. FY21 mission goal - driving research UK delivery ofresearch and partnerships In FY21 JDRF has built suc￿sSful new research partnerships and moved fotward in our strategic goals, despite the challenges of the ongoing pandemic. JDRF launched a new programme of Small Grant Awards in response to reF)Orts from the UK type 1 diabetes research community that ac￿SsIng larger funding programmes wilhoul preliminary data has become increasingly difficult. This is a pilot year for the programme, with the aim of this becoming a permanent feature of the UK funding ecosystem. We received a good volume of relevant high quality applications. The programme priorilises projects led by researchers who are al an early stage of their career, as this group of researchers experiences particular challenges in aecessing new research funding. Three Small Grant Awards were consequently made in June, following a robust process of review and discussion with the JDRF UK Scientific Advisory Council, which includes researchers, clinicians and people who live with type 1 diabetes. The projects supported by these awards are now getting underway in laboratories around the country. We will follow their progress closely, particularly with regard to how the awards help scientists secure follow-on funding. The Connect Immune Research partnership, developed by JDRF in Collaboration with Versus Arthritis, the MS Society and the British Society for Immunology to explore commonalities be￿een different autoimmune conditions, has continued to develop through FY21. Four new charities have joined the partnership, which has worked lo develop a partnership with another research funder, the Lom and YLJli Chernajovsky Biomedical Research Foundation. This led to the launch of a significant new funding opportunity for researchers working on translational projects in autoimmunity al the stsrt of FY22. We are excited to see where this opportunity will lead. Juvenile Diabetes Research Foundation Limited - _1.1 UK delivery of research and partnerships (continued)_ - _1.2 JDRF’s international research delivery and partnerships_ - _1.2 JDRF’s international research delivery and partnerships (continued)_ Dlrectors, report Year ended 30 June 2021 OUR THREE YEAR STRATEGY: FY21-23 Iconlinuedl FY21 Mission goal - Accelerating access to treatments Iconlinuedl JDRF delivered three stakeholder workshops as part of its Research lo Reality project, which aims lo accelerate the availability of emerging type 1 diabetes treatments and technology and put the priorities of people with type 1 al the forefront of research. The workshops shaped a roadmap of priority activity for the project. A report will be launched in FY22 identifying the barriers to type 1 emerging treatments and an Implementation plan for JDRF and stskeholders lo constructively improve aC￿ss. JDRF completed quants'lative and qualitative social research to map the impact of Covid on people affected by type 1 diabetes, including 40 in-depth interviews with those from groups hardest hil by the pandemic. The research provides insights into the mental and physical health of people with type 1 and the disruption lo NHS type 1 diabetes care during the pandemic. These insights form the basis of recommendations lo healthcare policy leaders to help reshape services in the future. A full report, Covid and Beyond, was launched in October 2021. FY21 Mlsslon goal - Provldlng Informatlon and support for people type 1 JDRF'S Community Engagement operation has transitioned from a regional to a national focus lo deliver trusted information, reSoUr￿S and support for people al different stsges of their type 1 journey, working with healthcare professionals and other stakeholders. A focus on reflecting lived experience has led lo JDRF being invited to judge the Quality in Care awards, which recognises good practice In patient care, for the third year running. JDRF'S printed materials have received good uptake and positive feedback, particularfy in light of the restrictions and challenges of the Covid pandemic. JDRF'S printed resources were accessed by over 6,000 adults and 9,800 families. General leaflets were distributed over 6,400 limes. Vvhile the range of printed materials are in general down from FY20, this is due lo the disruption and withdrawal of diabetes services as staff were redeployed lo support the surge care of patients admitted with Covid. However JDRF'S schools eLearning module was a¢￿ssed 30,647 limes lan increase of 175 percent on the previous yearl and has been a well-regarded education tool during the pandemic. JDRF has digilised and updated existing reSoUr￿s, creating web pages, e-downloads and online booklets to replace print materials. The move to digilisalion is an environmental prO￿sS with an estimated annual cost saving of £11,000. JDRF'S coronavirus information web page was the most read content on the website in 2021, with around double the number of visits to the home page during the same period the previous year. Over 80 percent of visitors were new to JDRF UK, enabling us lo reach new beneficiaries with information and support. Market research feedback has highlighted the value people with type 1 have placed on this clinically-approved and easy-to-access information about type 1 and Covid, given the risks and health uncertainties that our beneficiaries have faced during the pandemic. The coronavirus page functioned as both an important and trusted awareness tool and a cost effective way lo extend JDRF'S reach, and was well-received by healthcare professionals and the type 1 community. Juvenile Diabetes Research Foundation Limited Dlrectors, report Year ended 30 June 2021 OUR THREE YEAR STRATEGY: FY21-23 Iconlinued) FY21 Mission goal - Providing information and support for people type 1 Icontinuedl JDRF has developed a plan lo address health inequality and improve diversity in type 1 research, health policy and clinical practi￿. Our plan identifies the short-, medium- and long-term actions required lo meaningfully engage with 'hardly reached, groups alongside eommunily partners, and will underpin our information and support operations in FY22. JDRF has increased its information and support on medical technology for people living with type 1 to empower choice and improve health outcomes. In FY21, as a result of the pandemic, the charity Plvoted to virtual events in place of physical information events. The impact of this has been very positive. We were able to reduce costs and staff lime in terms of travel, event adminislralion and venue hire. The virtual events enabled JDRF to reach more benefi'ciaries across the UK and increase engagement. The result was that JDRF was able to double the number of events and treble the number of allendees al each event. Participant feedback showed people fell they had increased their knowledge about the range of treatment choices available, increased their confidence in using type 1 medical technology, and ine￿ased their skill in self-managing the condition using type 1 technologies. Throughout the year we updated our Infomialion and support web content, covering.. how to manage type 1., new technologies, such as the artificial pancreas., and other emerying new treatments. During the year JDRF established an impact and evaluation framework lo help us to continualty improve the quality of our support servI￿s. Looking Fonvard: A new strategy and approach The year ahead presents a high degree of uncertainty as to the continuing effects of the Covid pandemic on our work. We hold ourselves accountable through our governance and management processes to drive increased mission impact through and beyond the pandemic. The next year will be the second year of our three year strategy with the following goals.. Drive UK research to develop cures and improve lives for people with type 1 diabetes AC￿lerate aC￿sS lo type 1 treatments and technologies Deliver information and support to people living with type 1. We will support the growth of type 1 diabetes research in the UK. We will do this through our small grants awards, by developing new research partnerships in autoimmunity and by focusing on large scale partnership potential to increase the scale of type 1 diabetes research in the UK. Juvenile Diabetes Research Foundation Limited 10 Dlrectors, report Year ended 30 June 2021 OUR THREE YEAR STRATEGY: FY21-23 Iconlinuedl Looking Fonvard: A new strategy and approach Iconlinuedl We will advance the way that the UK can more systematically address the needs of people with type 1. We will do this by working lo establish a UK consensus on the quality of life priorities identified by people with type 1, and work to embed these as a focus for research, health service improvement and access to emerging Irealments. We will work lo accelerate and widen access to technology and treatments, rooted in lived experience insight, to help reshape NHS practice following the disruption caused by the pandemic. We will work to support regulatory approval for the use of the artificial pancreas on the NHS in 2022. We will sustain our focus on equality and diversity. We will develop a health equality programme of social research, information, support and policy influencing to reduce the socio-economic gap in health outcomes that we know exist for people with type 1. We will improve our use of digital tools, operations and data insight, which will improve the quality and effectiveness of our engagement with people affected by type 1, increase sustainable income and return on fundraising investment. We are grateful to the Steve Morgan Foundation and the Community Match Challenge for enabling us in the coming year to deliver a more responsive website, where people with type 1 can access more personalised content, information and support. Our values will guide our work, and with the insight and experience of our beneficiaries we will progress in our mission to eradicate type 1 diabetes. FY21 FINANCIAL REVIEW Summary The first UK Covid lockdown started four months before the end of our previous financial year. That year we were able lo sustain our income levels with an emergency appeal to our supporters, for which we were deeply grateful. In FY21 we fell the impact of the pandemic on our traditional sources of fundraising for the full year, which fell by more than 25 per￿n1 on the last full year before lockdown. However, due to the agility of our fundraising team, and the support and generosity of the Steve Morgan Foundation, we successfully applied for an award from the Govemment's Community Match Challenge Fund ICMCI, which again enabled us to keep income at the same level as in previous years. With the S percent growth in income achieved as a result of the award, and with reduced operational costs due to actions taken prior lo the award. we were able to increase research funding lo the highest level ever, both in absolute and proportionate terms. In addition, the strict timings of the CMC grant150 percent of the 30 month grant had lo be given by 31 March 20211, meant that our reserves ￿te1Ved a short term boost of £850,000. These funds will be spent over the next two years, sustaining JDRF in an uncertain time for normal fundraising activity. We do not expect our traditional fundraising activities to recover to pre- pandemic levels by June 2023, and plan lo fill the gap with a combination of new fundraising initiatives and the use of the short-lerm growth in reserves we achieved in FY21. Juvenile Diabetes Research Foundation Limited 11 Dlrectors, report Year ended 30 June 2021 FY21 FINANCIAL REVIEW Icontinuedl Income generation Income of £6.4m was 5 percent higher than the previous year IFY20'. £6.Oml. This included the third £1 m grant from the Steve Morgan Foundation to fund type 1 research projects In the UK. In addition to the value gained through the CMC award, in FY21 three generous individuals commenced a four year commitment lo give to the JDRF-inspired venture philanthropy vehicle in the United Stales, the T1 D Fund. As a result we were able to give lo the Fund a total of £270,000. All these valuable achievements were on lop of heroic efforts by 8 wide range of JDRF supporters who continued donating and fundraising, in new ways and old, during the unparalleled conditions of the past year. Expgnditure- research and other charitablo activities The amount spent on research advocacy and funding grew by 7 percent to £2.8m IFY20'. £2.63ml. UK and global research achievements during the year are described on pages six to eight. Despite the intensely challenging circumstances, JDRF has increased spending on research and advocacy proportionately more than the growth in income for each of the last five years in a row. JDRF'S support and awareness costs also g￿W slightly to £1.05m IFY20..£1.03ml, as we worked hard to provide up-to-date information lo people with type 1 as the pandemic progressed. Details of the activities and achievements of our work in these areas are described on pages nine to 10. Expenditure- costs of raising funds In FY21 JDRF reduced the cost of raising funds by 25 per￿nt lo under £1.67 million IFY20'. £2.24ml, despite achieving higher total income. This represents the many creative ways in which JDRF'S fundraisers and supporters responded lo the challenges of fundraising during the pandemic, and reflects the significant CMC award received during the year, amounting to 25 percent of our total income. JDRF Trading Limited These accounts consolidate the income, costs, assets and liabilities of JDRF Trading Limited with those of JDRF. This small wholly owned trading subsidiary enables JDRF to take advantage of opportunities to develop revenue from the corporate sector through sponsorship of certain events and activities benefiting people with type 1. The company produces separate accounts which can be obtained from JDRF'S Director of Finance and Resources and are summarised in note 11 to these accounts. Following significant growth the previous year, the trading company's income grew again this year to £282,000 IFY20'. £208,000), and operating profil for the year Igift aided In full to JDRFI also increased to £228,000 IFY20.' £157,000). Balance sheet for the charitsble group Cash and short-term deposits at 30 June 2021 lotalled £2.14m IFY20." £1.1 Sml. Cash is held in instant access and short-term deposit accounts that allow the best rale of interest at the level of risk deemed acceptable. Juvenile Diabetes Research Foundation Limited 12 Dlrectors, report Year ended 30 June 2021 FY21 FINANCIAL REVIEW Icontinuedl Balance sheet for the charitable group Icontinuedl Debtors al the year end were £424,000 IFY20." £411,000), of which £129,000 related lo accrued income IFY20.' £142,000). Of the total year end debtors figure, only £1,025 had not been received by November, and this is not considered al risk. Creditors were £438,000, a lit￿e higher than the low level of the previous year IFY20.. £310,000). Funds Restricted funds grew marginally during FY21 from £395,000 10 £407,000, showing that during the year we were able to use the £3.5m funds received for the purposes for which they were donated. UnrestriTCted funds increased from £1.Om lo £1.8m, because of the high proportion of the total CMC funds received by June. This short-lerm growth in funds held is expected lo reduce lo former levels over the next 12-24 months. Because of the growth in unrestricted funds, total funds held at the year end increased from £1.4m to £2.2m. The impact of these changes on JDRF'S reserves position is discussed under the relevant reserves policy paragraph below. JDRF flnances FY22 and beyond Conservative financial projections have been prepared to FY25, which broadly anticipate a return lo previous levels of fundraised income over the next four years, as existing support from the Government's Community Match Challenge Fund and from the Steve Morgan Foundation is reduced. This does not take awounl of possible significant new awards from the Foundation or from other donors. JDRF expects the traditional funding environment to remain uncertain for the foreseeable future. On a conservative estimate, the growth in funds experienced in FY21 will be spent over the next 12-24 months, sustaining JDRF'S core operational activity, and a critical level of research funding and other mission related expenditure. We will remain flexible and opportunistic in following up new income opportunities as they arise, maximising opportunity from existing donors and Contacts, and creating new ones when possible. As in the previous year, expectations for FY22 are based on a range of scenarios. These were affected by the notification in July 2021 that the London marathon due to lake place in April 2022 would be postponed lo October 2022. This will take our prospective net income from the event into the following financial year. As a result, on the low income scenario, our free reserves may drop close lo the lower end of our preferred policy range by the end of the year. However we are pursuing a number of funding opportunities early in the year that may result in significant gifts not included in the low income scenario being made before the year end. Juvenile Diabetes Research Foundation Limited 13 Dlrectors, report Year ended 30 June 2021 GOVERNANCE INFORMATION Public benefit and grant making policy The Directors have taken account of the Charity Commission's guidance on public benefit in reviewing JDRF UK'S aims and objectives and In planning future activities. JDRF UK aims to fund as much as possible of the globally approved research carried out in the UK. JDRF'S global research department provides details of the UK grant payments due on a monthly basis and JDRF UK pays those funded by restricted grants and donations and as much of the other grants as available funds and our reserves policies allow. Activity in Scotland JDRF has staff based in diffe￿nI parts of Seolland, supported by an active and capable volunteer group. We are well supported by the public across Scotland, which raises funds on JDRF'S behalf. Our fundraising activities in Scotland delivered £160,000 income during the year, lower than usual because of the ￿sIne￿.0nS due to the lockdowns during the year. In line with ils goal of funding the best research wherever it Is taking place in the world, JDRF funds type 1 diabetes research in Scotland and during FY21 funded projects al the Universities of Edinburgh and Dundee. JDRF fundraising statement Almost all our work driving the search to cure, Ireal and prevent type 1 diabetes, and all the work we do to help and support people affected by type 1 diabetes, is made possible by fundraising. In 2020 we were awarded funding by the Department of Digital, Culture, Media and Sport lo support our charity's resilience during and after the Covid pandemic. We receive no direct government funding towards our research. Fundraising is vital for our work, and we are passionate about building strong, long lasting relationships with our supporters through considerate, ethical fundraising and supporter care. We use a range of recognised methods to raise funds. This includes working with trusts and foundations, philanlhropisls, businesses, schools and clubs, and individuals who take part in our fundfftising events, run fundraising events of their own, respond to our appeals or donate direcuy lo us. Our fundraising team leads on this work, with almost all of the fundraising activity being managed in-house. It is supported from lime to lime by a professional telephone fundraising agency whose small team we have worked closely with over the last seven years, and who we engage to speak with supporters on our behalf. As we resume our event fundraising post-pandemic, we are careful to adhere to government guidan￿ on Covid-19 and we review this as part of our risk assessment when planning and holding in-person events. Ahead of physical events, we provide our supporters with relevant information that they may wish to consider such as limited attendee numbers and ventilation, and we encourage them to follow a short list of relevant guidelines to help keep both our stsff and supporters safe. Juvenile Diabetes Research Foundation Limited 14 Dlrectors, report Year ended 30 June 2021 GOVERNANCE INFORMATION Iconlinued) Fundraising on our behalf lthen we do appoint a fundraising agency we ensure their work on our behalf is both effective and aligned with our values and responsibilities. The agency that we use is a corporate member of the Chartered Institute of Fundraising, registered as a commercial supplier with the Fundraising Regulator, and complies with the codes of behaviour of both organisalions. In line with recommendations from the Fundraising Regulator we train agency fundraisers according lo our standards and expectations and we conduct regular call monitoring. Our Supporter Promise We developed our supporter promise to make sure that everyone who comes into contact with us is respected and valued, and lo let them know that their data is safe and secure with us. Our supporter promise can be found at htt s.Il'drf.or .ukl et-involvedl iveldonalion- v21our-su orter- romise. To date we have re￿iVed three suppression requests from the Fundraising Preference Servi￿. All three requests were resolved in line with Fundraising Preference Service rules and our own internal procedures. Further fundraising regulation We are registered with the Fundraising Regulator and adhere to ils code of Fundraising Practi￿. JDRF is a member of the Institute of Fundraising. We are committed to best practice in fundraising and lo complying with all statutory regulations, including the Charities Act 2016, the General Data Protection Regulation, the Privacy and Electronic Communications Regulations 2003 and the Mailing and Telephone Preference SeNices. Complaints During FY21, we received five complaints 8bout our fundraising activities, none of which were related to intrusion of privacy, unreasonable persistence or pressure lo give. All complaints were resolved satisfactorily, with none being referred to extemal regulatory bodies. Protecting Vulnerable Supporters Our supporters are al the heart of everything we do, and we understand that protecting those that may be in vulnerable positions is crucial for safe and effective fundraising. Our external fundraisers receive training in recognising vulnerable people. We lake steps to ensure our telemarketing campaigns avoid unreasonable intrusion on our supporters, privacy, including not making telemarketing calls during unsociable hours and limiting the number of limes we call unanswered numbers. We limit the number of times we make financial requests for support in a single call in order to avoid applying undue pressure. We monitor and limit the number of mail, email and telephone communications we send to supporters asking for their financial support, ensuring requests are not unreasonably persislenl. Juvenile Diabetes Research Foundation Limited 15 Dlrectors, report Year ended 30 June 2021 GOVERNANCE INFORMATION Iconlinued) Financial policies and activities Reserves policy The Board is committed to ensuring a sound financial base for JDRF'S work and activities. The Board has adopted a reserves policy which is designed to assist with managing reasonable levels of risk, making funds available for future activities and providing for cash flow movements, while maximising the flow of funds lo research. The Board reviews ils reserves policy with reference lo Charity Commission guidelines every two years, and took a new approach to calculating an appropriate range of reserves during the year. The policy look a range of historical costs and movements on income, and pooled these to establish high and low points for unreslricled cash balan￿s. On this basis the board has determined that it expects JDRF to hold under normal circumStan￿S unreslricled cash between £0.6m and £O.gm. On aveoge over recent years, the ratio of unreslricled cash to free reserves has been 1.. 1.4, which gives rise lo a free reserves range of £0.84- £1.26m. As noted above, JDRF received significant levels of support during FY21, which is intended to provide support through to 2023. As a result, our free reseNes have increased significantly in the short-lerm, standing at £1.7m at the year end, approximately £0.5m above the target range. With a challenging year expected in FY22, unrestricted cash levels and free reserves are expected lo return to the new policy range in the last few months of the year. Rlsk management and mltlgatlon The Board monitors the principal business and control risks to JDRF, within a control framework. The risk assessment register is reviewed at least ￿1Ge a year by senior management and updated accordingly. Following a review, the format and contents of the register have been updated during the year. Severity and likelihood definitions have been added, and the treatment of risk outcome scores identified. Pre- and post-mitigation scorings have been added lo add clarity and dynamism. Strategies and timelines have been agreed for the management and limitation of identified risks, the most important of which have been reviewed by the Audit and Risk Committee and the Board. Al present JDRF has no red risks (risk score 15+1 and three amber risks (risk score 9-121. The highest scored risk1121 relates to relative dependence at present on a single funder (the Steve Morgan Foundation, SMFI. SMF awarded JDRF a three year grant of £3m restricted to ￿search funding which ended in June 2021. While a further pledge of £1 m towards research has been made by SMF, this is expected to be spent over several years. Al a lime when fundraised income has been affected by pandemic lockdowns, this is likely to affect the amount of research JDRF can fund in FY22 and subsequently, unless new equivalent amounts for research can be raised. The second highest risk191 relates lo a possible reduction of funding priorities in the UK by the global research funding department at JDRFI in the US. This could be a consequence of reduced income in the US due lo the pandemic. Lower levels of JDRFI research funding in the UK could affect JDRF'S profi'le with UK type 1 researchers, and make il harder to raise money for research from UK donors. Juvenile Diabetes Research Foundation Limited 16 Dlrectors, report Year ended 30 June 2021 GOVERNANCE INFORMATION Iconlinued) Risk management and mitigation Icontinuedl The remaining risk (also 91 Is dLJe to the possible impact on a charity the size of JDRF should a number of key staff leave over a short period of time. JDRF has developed policies and good practice aimed at staff retention and talent management, and reviews succession planning for critical roles on a regular basis. Financial controls review In the autumn of 2021 the Audit and Risk Committee and the Board reviewed the updated summary of JDRF'S internal financial controls and fraud risks, using the template of the Charity Commission's CC8 guidelines on Internal Finance Controls for Charities. This thorough exercise concluded that JDRF'S internal controls and processes are appropriate to its activities and that risks are miligaled appropriately and proportionately. STRUCTURE. GOVERNANCE AND MANAGEMENT JDRF is a charitable company limited by guarantee incorporated on 6 November 1986 and registered as a charity on 14 May 1987. The objects and powers of the company are sel out in, and governed by, its articles of association. New articles of association were adopted in 2017, reflecting LJP-t(hdate law and practice. JDRF is governed by a Board of Directors, the members of which are also the trustees of the charity for the purposes of charity law, which meets al least five times a year. The Board sets the strategic goals of JDRF, reviews the pursuit of charitable objectives, establishes policy, and monitors financial status and Complian￿ with legal requirements. The Chief Executive assists the Board in these activities and together with the staff is responsible for the implementslion of the charity's strategic plan and the day to day running of JDRF. The Board of Directors h8s established Committees that report and are accountable to the Board. the Succession and Development Committee and the Audit and Risk Committee, lo assist in the efficient execution of ils responsibilities and duties. In addition the Board has more informal progress meetings between the quartedy Board business meetings at which there is the opportunity lo hear updates on current issues or have fuller discussions of wider matters of interest. The SUc￿sSion and Development Committee Imade up of at least three current or former Directors and an independent recruitment expertl meets as needed and is responsible for identifying and recruiting new Directors and ensuring retention and development of senior level volunteers. During the year the Committee concluded recruitment for three new Board Directors, including a replacement for the Treasurer who retires at the end of 2021. The Audit and Risk Committee is ￿SponSible for JDRF'S compliance with statutory reporting, managing the relationship with the external auditor, reviewing the draft accounts and accompanying report, JDRF'S risk management and a range of financial controls and processes. This Committee is made up of the TreaSU￿r, at least one other Director and an appropriately qualifiedlexperienced extemal expert, is attended by the Director of Finance and Resources and Head of Finance and meets or three limes a year. The Committee has led on the refreshed approach lo risk management that has been implemented during the year, and on the newly drafted reserves policy. Juvenile Diabetes Research Foundation Limited 17 Dlrectors, report Year ended 30 June 2021 STRUCTURE. GOVERNANCE AND MANAGEMENT Iconlinuedl Appointment of Directors All potential Directors of JDRF go through a nomination process before they join the Board. This is within the remit of the Succession and Development Committee which has the goal of identifying and Meeting individuals who have the necessary skills, experience and leadership attributes that will further JDRF'S mission to find the cure for type 1 diabetes. Directors are appointed by the Board and serve an initial term of three years but may be reappointed for a further term of three years. Induction of new Directors Prior to appoinlmenl, potential Directors Meet our Chief Executive, Chairman, and representatives from the sU￿sSion and Development Committee to discuss the work of a Board Director in depth and the expectations and responsibilities of the role. They are given an overview of organisational history, current activities and strategy. Following their appointment to the Board, new Directors have a series of induction meetings with members of our senior management team and are given key documents including JDRF'S articles of association, its most recent annual report and accounts and a range of other documents and publications. Training of Directors Collective and individual training on issues of strategy and governance is offered lo Directors. Remuneration of key management personnel The executive team consists of the Chief Executive and five Director of Department roles.. Research Partnerships, Policy and Communications, Fundraising and Engagement, Finance and Resources and People and Operations, as detailed in the reference section on page 21. JDRF is committed to being open about the work that we do to achieve our mission. JDRF'S approach to pay and reward is that this should enable us to recruit and retain the skilled stsff we need to create a wodd without type 1 diabetes. We believe that it is reasonable for the charity sector lo pay a fair salary for the skills and the experience needed lo run a professional, cost-effeclive and SUC￿ssful charity. All JDRF stsff, including the senior management team, are normally eligible for an annual cost of living pay award, and a progression pay scheme that rewards staff who make a significant contribution to JDRF. The amount paid lo senior staff reflects the market forjobs in comparable organisations, the performance of the organisalion and the skills and contribution of the individual performing the role. Benefits for all staff include a matched pension contribution of 40/0 of salary, which increases with Servi￿ as detailed on page 35. Salaries of JDRF'S senior staff are reviewed biennially against the market by a specialist pay and reward consultancy and are sel by the Board. Juvenile Diabetes Research Foundation Limited 18 Dlrectors, report Year ended 30 June 2021 STRUCTURE. GOVERNANCE AND MANAGEMENT Iconlinuedl Volunteers Volunteers play a vital role at JDRF. During the year volunteers served on development groups within the regions and in groups supporting national fundraising teams and activities. All Board Directors and advisors from the scientific community give their time free of charge. In addition, volunteers help JDRF with many aspects of ourwork, especially with fundraising events and with office aclivilies. In FY21 over 600 individuals volunteered lo support JDRF, and we are extremely grateful lo all of these dedicated supporters. STATEMENT OF DIRECTORS. RESPONSIBILITIES The Directors are responsible for preparing the trustees, report and the finaneial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounts'ng Practice). Company law requires the Directors to prepare financial statements for each financial year which give a true and fair view of the slate of affairs of the company and the group and of the incoming resour￿5 and application of resources, including the income and expenditure, of the group for that period. In preparing these financial statements, the Directors are required lo". select suitable accounting policies and then apply them consislenlly", observe the methods and principles in Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland IFRS 1021, make judgments and estimates that are reasonable and prudent., state whether applicable United Kingdom Accounting Standards have been followed, subject lo any material departures disclosed and explained in the financial slalemenls., and prepare the financial statements on the going concem basis unless il is inappropriate to presume that the company will continue In operation. The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005 and the Charities Accounts (Scollandl Regulations 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. Juvenile Diabetes Research Foundation Limited 19 Dlrectors, report Year ended 30 June 2021 STATEMENT OF DIRECTORS. RESPONSIBILITIES Iconlinuedl Each of the Directors confitms that. so far as the Director is aware, there is no relevant audit informab'on of which the company's auditor is unaware., and • the Director has taken all the steps that they ought lo have taken as a Director in order lo make themself aware of any relevant audit information and to establish that the company's auditor is aware of that information. This confirmation is given and should be interpreted in accordan￿ with the provisions of s418 of the Companies Act 2006. Members of the company guarantee to contribute an amount not ex￿edIng £10 to the assets of the company in the event of winding up. The total number of guarantees at 30 June 2020 was 9. The Directors have no beneficial interest in the company but as members are entitled to voting rights. AUDITORS Buzzacott LLP was reappointed auditor by the Board for the year ended 30 June 2022 and has expressed Ils willingness to act in that capacity. Approved by the Directors on 13 December 2021 and signed on their behalf by David M¢Turk David McTurk Chair Juvenile Diabetes Research Foundation Limited 20 Reference and admlnlstratlve detalls President Her Royal Highness The Duchess of Cornwall Directors The Directors, who are also trustees under charity law, who served during the year up to the dale of this report were as follows.. Phil Aird-mash (Vice Chair from June 2021 Barrie Brien Jared Chebib (appointed De￿mber 2020, Treasurer from July 20211 Christina Croft Wilson Leech (appointed De￿rnber 20201 Karen Loumansky (resigned December 20201 Per LLJndin (appointed March 20211 James Lurie David McTurk (Chairl lan Schneider (Treasurer until June 20211 Company Secretary Jonathan Taylor Executive management team Chief Executive Director of Fundraising & Engagement Karen Addington James Elliott lunlil March 20211 Mike Straney (from May 20211 Rachel Connor Hilary Nathan Jonathan Taylor Hayley Anderson Director of Research Partnerships Director of Policy and Communications Director of Finance and Resources Director of People and Operations Registered office 17118 Angel Gate City Road London EC1V 2PT Telephong T.. 020 7713 2030 F.. 020 7713 2031 E.. info .uk Website Juvenile Diabetes Research Foundation Limited 21 Reference and admlnlstratlve detalls Social media JDRFUKlhll s'.1/￿1tter.C0mI'drfuk JDRFUKlhll s.Ilwww.faeebook.comlJDRFU KIJDRFUK JDRFUKlhtt s'.Ilww.linkedin.comlcom f-UK JDRFUKlhtt s.'IlwNw.insta an ram.comldrfukl Company registration number 02071638 (England and Wales) Charity registration numbor 295716 (England and Wales) SC040123 (Scollandl National and regional offices JDRF Scotland.. Aberdeen Office T: Aberdeen.. 01224 248 677 T: Central Scotland. 07790 572188 E." scotland Auditor Buzzacoll LLP 130 Wood Street London EC2V 6DL Bankers Barclays Bank plc Marble Arch Corporate Banking Group PO Box 32016 London NW1 2ZH Juvenile Diabetes Research Foundation Limited 22 Independent audltor's report 30 June 2021 Independent auditor's report to the members of Juvenile Diabetes ReSea￿h Foundation Llmlted Opinion We have audited the financial statements of Juvenile Diabetes Research Foundation Limited I'the charitable parent company'l and its subsidiary Ilhe 'group'l for the year ended 30 June 2021 which comprise the consolidated statement of financial activities, group and charitable parent company balance sheets and consolidated statement of cash flows and notes lo the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, (United Kingdom Generally Accepted Accounting Practice). In our opinion, the financial statements.. give a true and fair view of the slate of the group's and of the eharilable parent eompany's affairs as at 30 June 2021 and of the group's income and expenditure for the year then ended., • have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice", and have been prepared in accordance with the requirements of the Companies Act 2006, the Charities Act 2011, the Charities and Trustee Investment Iscotlandl Act 2005 and regulation 8 of the Charities Accounts (Scollandl Regulations 2006 las amended). Basis for opinion We conducted our audit in accordance with Intemalional Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate lo provide a basis for our opinion. Conclusions relating to going concern In auditing the financial ststemenls, we have concluded that the trustees, use of the going concern basis of aceounling in the poparalion of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating lo events or conditions that, individually or collectively, may cast significant doubl on the group and charitable parent company's ability lo continue as a going concern for a period of al least twelve months from when the financial statements are aulhorised for issue. Juvenile Diabetes Research Foundation Limited 23 Independent audltor's report 30 June 2021 Conclusions relating to going concern Iconlinued} Our responsibilities and the resFX)nsibilities of the directors with respect to going concem are described in the relevant sections of this report. Othor information The trustees are responsible for the other information. The other information comprises the information included in the directors, report other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the exlenl othetwise explicitly ststed in our report, we do not express any form of assurance conclusion the￿on. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required lo determine whether there is a material misstalemenl in the financial statements or a material misstalemenl of the other information. If, based on the work we have performed, we conclude that there is a material misstalemenl of this other information, we are required to report that fact. We have nothing lo report in this regard. Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit.. + the information given in the directors, report for the financial year for which the fin8nci81 stslements are prepared is consistent with the financial statements., and the directors, report has been prepared in accordance with applicable legal requirements. Matters on which we are required to report by exception In the light of the knowledge and understsnding of the group and the charitable parent company and ils environment obtained in the course of the audit, we have not identified material misstatements in the directors, report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotlandl Regulations 2006 las amended) requires us to report lo you if, in our opinion.. proper and adequate accounting records have not been kept by the charitable parent company, or returns adequate for our audit have not been received from branches not visited by us., or + the charitable parent company financial statements are not in agreement with the accounting records and retums,. or rtain disclosures of directors, remuneration specified by law are not made,. or Juvenile Diabetes Research Foundation Limited 24 Independent audltor's report 30 June 2021 Matters on which we are required to report by exception Icontinuedl we have not received all the information and explanations we require for our audit", or + the trustees were not entitled lo prepare the fi'nancial statements in accordance with the small companies regime and take advantage of the small companies, exempb'ons in preparing the directors, report and from the requirement to prepare a strategic report. Responsibilities of trustees As explained more fully in the directors, responsibilities ststemenl, the Iruslees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such Internal control as the trustees determine is necessary lo enable the preparation of financial statements that are free from material misstatement, whether due lo fraud or error. In preparing the financial statements, the Iruslees are responsible for assessing the group's and the charitable parent company s ability lo continue as a going concern, disclosing, as applicable, matters related to going concern and using the going Concern basis of accounting unless the trustees either intend lo liquidate the group or the charitable parent company or to ase operats'ons, or have no realistic alternative but lo do so. Auditor's responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and lo issue an auditor's report that includes our opinion. Reasonable assuranee is a high level of assurance, bul Is not a guarantee that an audit conducted in accordance with ISAS IUKI will always detect a material misslatemenl when il exists. Misstalemenls can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected lo influence the economic decisions of users taken on the basis of these financialstatements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to dete¢l material misstalemenls in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. Our approach lo identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-complian￿ with laws and regulations, was as follows.. the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills lo identify or recognise non-complian with applicable laws and regulations., and • we obtained an understanding of the legal and regulatory frameworks that are applicable to the group and parent charity and determined Ihatthe most significantframeworks which are directly relevant lo specific assertions in the financial statements are those that relate to the reporting framework Istalement of Recommended Practice.. Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland IFRS 1021, the Charities Act 2011, the Charities and Trustee Investment Iscotlandl Act 2005 and regulation 8 of the Charities Accounts Iscotlandl Regulations 2006 las amendedll, and those that relate to fundraising including The Code of Fundraising Practice. Juvenile Diabetes Research Foundation Limited 25 Independent audltor's report 30 June 2021 Auditor's responsibilities for the audit of the financial statements Icontinuedl We assessed the susceplibilily of the group's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by.. making enquiries of management as to their knowledge of actual, suspected and alleged fraud,. and considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations. To address the risk of fraud through management bias and override of controls, we.. • performed analytical procedures to identify any unusual or unexpected relationships., • performed substantive testing on expenditure including the authorisalion thereof., • tested journal entries lo identify unusual transactions., and assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias. In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to.. reading the minutes of meetings of those charged with govemance., and enquiring of management as to actual and potential liligalion and claims. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Iruslees and other management and the inspection of regulatory and legal Correspondence, if any. Material misslatemenls that arise due lo fraud can be harder lo detect than those that arise from error as they may involve deliberate concealment or collusion. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uklauditorsresponsibilities. This description forms part of our auditor's report. Juvenile Diabetes Research Foundation Limited 26 Independent audltor's report 30 June 2021 Use of our report This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charity's trustees as a body, in accordan￿ with Section 44{1 Ilcl of the Charities and Trustee Investment (Scollandl Act 2005 and Regulation 10 of the Charities Accounts Iscollandl Regulations 2006. Our audit work has been undertaken so that we might stale to the charitable company's members those mallers we are required lo slate to them in an audilorfs report and for no other purpose. To the fullest extent pemiitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed. Buzzacott LLP 17 March 2022 Edward Finch (Senior Statutory Auditor) For and on behalf of Buzzacott LLP, Statutory Auditor 130 Wood Street London EC2V 6DL Buzzacott LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006. Juvenile Diabetes Research Foundation Limited 27 Consolidated ststement of financial activities Year to 30 June 2021 Totsl fund¥ 2021 Total funds 2020 Unre8tricted Restricted funds funds Unrestricted Restricted funds funds Notes Income and 8xpenditurg Income Donations and legaaes Other trading activities Charitable activities Rese8rch grants Support and awareness Interest receivabl8 Total income 1 2,003.287 879,746 643,871 2,647.158 2,506,246 879.746 1,821.321 531,421 3,037,666 1.821,321 1.084,680 1,084.680 1,761,000 1,761,000 3.062 5.135 3,489,551 6,375,646 4,332,702 1,100,5 80,131 1,100,500 80,131 5,135 1,712,052 6,044,754 3.062 2,886,095 EX￿nditur* Cost of raising fvnds Charitable activities Research funding . Research advocacy Subtotal research expenditure 975.106 695,743 1,670,849 2,243,583 2.243,583 428,484 205.285 633,769 1.940,655 2,369,139 881.409 237,234 442.519 400,547 2,177,889 2,811,658 1,281.956 1.348.219 2.229,629 400,547 1.348,219 2.630,176 Support and awareness Subtotal charitable activities 445,319 1,079,088 604,318 1,049,637 939,770 2.782,207 3,861,295 2,221.727 85,983 1,025,733 1.434,183 3.655,909 Total expendlture 4 2,054.194 3,477,950 5,532.144 4,465,310 1,434,182 5,899,492 Nèt ineom• l•xp•nditur•l and n•t movement in funds 831.901 11,601 843.502 1132,6081 277,870 145,262 Rèeoneiliation of funds Total funds brought forward at 1 July 2020 98S,322 39S,156 1,380,478 1,117,930 117,286 1,235,216 Total funds carried forward al 30 June 2021 16 1,817.223 406,757 2,223,980 985.322 395.156 1.380,478 All of the above results are derived from continuing activities. All recognised gains and losses are included in the above statement of financial activities. Juvenile Diabetes Research Foundation Limited 28 Balance sheets 30 June 2021 Group Charity 2021 2020 2021 2020 Notes Fixed assets Tangible assets Investments 97,078 115,891 97,078 10,001 107,079 115,891 10.001 125,892 10 97,078 115.891 Current assets Debtors 8sh at bank and in hand 423.647 2,140,797 2,564.444 410,551 1.164.023 1,574,573 520,293 1,876,628 2,396,921 443,475 998.431 1,441,906 Liabilities Creditors.. amounts falling due within one year Net current assets 14 437.542 2,126.902 309.986 1,264,587 280,020 2,116,901 187,319 1,254,586 Total net assets 15 2,223,980 1,380.478 2,223,980 1,380.478 The fLJnds of the charity.. Funds and reserves Restricted funds Uniestiicted funds General funds 16 406,7S7 395,156 406,757 395,156 1,817,223 2,223,980 985,322 1,380.478 1,817,223 2,223,980 985,322 1.380,478 Approved by the directors on 13 December 2021 and signed on their behalf by.. David McTurk Jared Chebib David McTurk Chair Jared Chebib Treasurer Company Registration Number.. 02071838 (England and Wales) Juvenile Diabetes Research Foundation Limited 29 Consolidated ststement of cash flo￿￿ 30 June 2021 2021 2020 Notes Cash flows from operating activities: Net cash provided (used inl by operating 8ctivib.es 986,499 1197,4801 Cash flows from investing activities.. Interest received Purchase of tangible fixed assets Net cash used In Investlng aetlvltles 3,062 112,7871 19,7251 5,135 180.1801 175,0451 Change in ¢a¥h and ¢08h equivalents in the year 976,774 1272.5241 Cash and eash èquivalènts at 1 July 2020 B 1.164,023 1,436,547 Cash and cash equivalents at 30 June 2021 8 2.140,797 1,164,023 Notes to the statement of cash flows for the year to 30 June 2021. A Reconclllatlon of net movement In funds to net cash provlded by operatlng actlvltles 2021 2020 Net movement in funds las per the statement of financial activities) Adjustments for= Depreciation charge Interest receivable Ilncreasel decrease in debtors Increase Idecreasel in creditors Net cash provided by lused in) operating activities 843,502 145,261 31,599 13,0621 113,0961 127,556 986,499 31,612 15,1351 187.181 1558,3981 1197.4801 B Analysis of changes in net debt At1 July 2020 Movement in year At 30 Jun• 2021 Cash at bank and in hand Totsl cash and cash equivalents 1,164,023 1,164.023 976,774 976.774 2,140,797 2,140,797 Juvenile Diabetes Research Foundation Limited 30 Principal accounting policies 30 June 2021 The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the accounts are laid out below. Basis of preparation These financial statements have been prepared for the year lo 30 June 2021. The financial statements have been prepared underthe historical cost convention with items recognised al cost or transaction value unless otherwise slated in the relevant accounting policies below or the notes lo these financial statements. The financial statements have been prepared in accordance with Accounting and Reporting by Charities". Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (Charities SORP FRS 1021, the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 and the Companies Aet 2006. The charity conslilutes a public benefit entity as defined by FRS 102. The financial slalements are presented in slerfing and are rounded lo the nearest pound. Basls of Consolldatlon The statement of financial activities and balance sheet consolidate the assets, liabilities, income and expenditure of the charity and ils wholty owned subsidiary undertaking, JDRF Trading Limited. The results of the subsidiary undertaking are consolidated on a line-by-line basis. No separate statement of financial activities or statement of cashflows has been prepared for the charity above as permitted by Section 408 of the Companies Act 2006. Critical accounting estimates and areas of judgement Preparation of the financial slalements requires the trustees and Management to make signifi¢antjudgemenls and estimates. The items in the financial statements where these judgements and estimates have been made include.. + assessing the probability of receipt of legacy income., allocation of support and governance costs.. estimating the useful economic life of tangible fixed assets for the purposes of determining a depreciation rate., and estimating fvjture income and expenditure flows for the purpose of assessing going concern (see below). Juvenile Diabetes Research Foundation Limited 31 Principal accounting policies 30 June 2021 Assessment of going concern The trustees have assessed whelherthe use of the going concem assumption is appropriate in preparing these financial slatemenls. The trustees have made this assessment with respect to a period of one year from the dale of approval of these financial statements. The trustees of the charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubl on the ability of the charity to continue as a going concern. In making this assessment, the trustees have considered the impact of the Coronavirus outbreak on the group and charity, specifically they have considered the availability of future funding from grants and donations and the ability to continue lo fund charitable activities through available reserves. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due. Income recognition Income is recognised in the period in which the charity has entitlement lo the income, the amount of income can be measU￿d reliably and it is probable that the income will be received. Income reTrived by way of subscriptions, donations and gifts to the charity is included in full in the statement of financial activities when receivable. Donations are recognised when the charity has confirmation of both the amount and settlement date. In the event of donations pledged but not received, the amount is accrued for where the receipt is considered probable. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled lo the funds, the income is deferred and not recognised until either those conditions are fLJlly mel, or the fulfilmenl of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period. Donated services and facilities provided to the charity are recognised in the period when il is probable that the economic benefits will flow to the charity, provided they can be measured reliably. This is normally when the service is provided. An equivalent amount is included as expenditure. Donated services and f8cililies are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing lo pay to obtain facilities or services of equivalent economic benefits on the open market. Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that the￿ are sufficient surplus assets in the estate lo pay the legacy, and any conditions attached to the legacy are within the control of the charity. Juvenile Diabetes Research Foundation Limited 32 Principal accounting policies 30 June 2021 Income recognition Icontinuedl Enlillemenl is taken as the earlier of the dale on which either.. the charity is aware that probate has been granted, the estate has been finalised and notifi'cation has been made by the executor to the charity that a distribution will be made, or when a distribution is received from the eslale. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a dislribulion. Where legacies have been notified lo the charity, or the charity is aware of the granting of probate, but the criteria for income recognition have not been mel, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having being transferred to the charity. Revenue grants are credited to the statement of financial activities when received or receivable whichever is earlier. Where unconditional entitlement lo grants re￿1vable is dependent upon fulfilment of conditions within the charity's control, the incoming resources are recognised when there is sufficient evidence that conditions will be mel. Where there is uncertainty as to whether the charity can meet such conditions the incoming resource is deferred. Interest on funds held on deposit is included when re￿1vable and the amount can be measured reliably by the charity., this is normally upon notificats'on of the interest paid or payable by the bank. Resources expended Liabilities are recognised as expenditure as soon as there is a legal or conslruclive obligation committing the charity to make a payment lo a third party, il is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis. Expenditure is allocated to a particular activity where the cost relates directly lo that activity. Expenditure includes attributable VAT which eannol be recovered. The cost of overall direction and administration of each activity, comprising the salary and overhead costs of the ￿ntral functions, is apportioned on the basis of an eslimale, based on staff lime, of the amount attributable to each activity. Premises and office costs are allocated based on the amoLJnt of floor space attributable to each activity, except for regional offi￿8 which are split 75'/o cost of generating funds, 5,10 research advocacy and 200/0 SUPPOrt and awareness. Governance costs are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional 2nd statutory requirements and include any costs associated with the strategic management of the charity's aclivilies. Juvenile Diabetes Research Foundation Limited 33 Principal accounting policies 30 June 2021 Resources expended Iconlinuedl The costs of raising funds relate lo the costs incurred by the group in raising funds for the charitable work. Where information about the aims, objectives and projects of the charity is provided lo potential beneficiaries, the costs associated with this publicity are allocated to charitsble activities. Where such information about the aims, objectives and projects of the charity is also provided lo potential donors, activity costs are apportioned be￿een fundraising and charitable activities. Grants payable are charged lo the statement of financial activities in the year in which agreement lo pay has been reached with JDRF'S global research department. Provision is made for grants agreed and approved but unpaid al the period end. Tangible fixed assets Items of equipment are capitalised where the purchase price exceeds £1,000 including irrecoverable VAT. Depreciation is provided at rates calculated lo write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows. Leasehold Improvements Over the lifetime of the lease + Computer equipment 5 years + Fixtures and fittings 5 years Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their Carrying value may exceed their net realisable value or value in use. Investments Investments held as fixed assets comprise shares in the charity's subsidiary trading company and are staled at cosL Debtors Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments 8re valued at the amount prepaid. Cash at bank and in hand Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition. Credltors and provlslons Creditors and provisions are recognised when there is an obligation at the balance sheet dale as a result of a past event, il is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the charity anticipates il will pay to sellle the debt. Juvenile Diabetes Research Foundation Limited 34 _Financial assets_ _Cash at bank_ _Financial liabilities_ Notes to the financial statements 30 June 2020 I Income from donations and legacies Totsl funds Unrestricted Restricted 2021 funds funds Tol81 funds 2020 Unrestrictsd R8strictsd fvJnd8 fund8 Donations Legac￿$ Third party fundraising Total 1,605,904 $63,871 2,169,775 41.900 80,000 121,900 355,483 355,483 2,003.287 2,647,158 1.934.819 531,421 2.466.239 67.608 67,808 503.819 503,819 2.506.246 3.037.866 643,871 531,421 2 Income from tradlng actlvltles Total fund$ UnreslriGted Restri¢ted 2021 fund5 fund5 Tol81 fund5 2020 UnrestriGted Restri¢ted fvnds One Walk 26.087 378,063 26,087 378,063 109.004 589.241 109,004 589,241 Running and challenge event5 Corporatè Sponsorship, advertising and merchandise Events and other fundraising 287.571 2B7,571 234.196 234,196 91,899 31.014 91,899 31,014 776.449 38,345 776,449 38,345 RÈnlaVolher Income Coronavims Job Retention Scheme Totsl 65.112 65,112 74.086 74,086 879.746 879,746 1.821.321 1,821,321 3 Income from charitable activities 2021 Totsl R8stricted 2020 Total Restricted ResearGh grant5 The Steve Morgan Foundation The Alan & Babette Sain5bury Charitable Fund Th& Cadogan Charity The Mason L8 Page Charitable Trust Miss Margaret Butlers Reekie Charitable Trust The R S MaGdon4￿ Charitsble Trust Nimar Charitable Trust The Henry Lumley Ch8rilabk Trust Conlribulion5 £5,000 or le55 1,000,000 1,000,000 24.000 50.000 5,000 50,000 5,000 10,000 5,000 5.000 16.500 1.100.500 14,680 1,084,680 Support and awareness D8parim8nt for Digital, Culture, Media and Sport (Communty match chalkngel The Steve Morgan Foundatio Co￿St0￿e$ Chariiabk Trust Th& Mercer8' Company The Hugh Fraser Found81ion Humtningbird Charitable Trust Garfi&kJ Weston Foundation Contributions £5,000 or less 1,500,000 187,500 15,000 5,000 7,500 45,000 75.000 5,131 80.131 1,000 1,761,000 Total 2,B45,680 1.180.631 Juvenile Diabetes Research Foundation Limited 36 Notes to the financial statements 30 June 2020 4 Total expenditure Totsl funds Unrestricted Restricted 2021 funds funds Tol81 funds 2020 Unrestrictsd R8strictsd fvJnd8 fund8 Costs of raising funds 975,106 695,743 1,670,849 2.243.583 2.243,583 Charitable activities Research funding Resear¢h advo¢acy Support and awareness Total 428A84 1,940,655 2,369,139 205.285 237,234 442,519 445.319 604,318 1,049,637 2,054,194 3,477,9SO S,532,144 881.409 1,348,219 2,229,629 400.547 400,547 939,770 85,963 1,025,733 4.465.310 1,434,182 5.899.492 Cost of Support ralslng Research Research and Governance runds fundlng advocacy awareness costs Support costs 2021 Total Note Staff costs Other Stsffing CDSt$ Office costs Rentand premlses Depreciation InfOr￿lI0n lechnokngy c051s 974,503 4,322 47,6U9 140,523 226,$58 393 7,153 18,094 236,624 21,91S U,923 17,241 471,Q64 27,927 15,467 45,165 1114099 181 993 2,866 27S,115 2,287,961 13,183 67,924 19,175 98,400 40,949 264,818 31.599 31,5Y9 22,Q18 110,604 51,717 9,729 7,681 17.923 1,636 Direct fundraising Costs Dtyn¥bon¥ and 8PP*81$ Third party fundraising . One Walk RunDing and thallenge events 112,317 112.387 £,243 6,243 52,4Q7 52,407 Events and olher 9,318 9.318 Subtoial dire¢t lundral$in9 cos 181,160 181,160 Audit fees 12.545 7,427 12.545 7,427 88,220 341,13S Governan Advoca¢y supp￿ atbd awareness Research grants- unresthcted 5,875 341,135 246,797 1,793.554 1.399,914 2,306.151 204,749 47,601 66,186 15,387 1,670,849 2,369,139 246,797 1,793,554 401,D39 5,532.144 1401,11391 Researth grants- restrcted 3T6,T32 918,671 49,716 98,973 16,071 31,993 442,519 1,049,637 129,537 Supwrt costs Govemantr¢o$ts 1129,6371 Total •xpAndltur• 2021 5,532,144 Juvenile Diabetes Research Foundation Limited 37 **----- Start of picture text -----**
Cost of Support
raising Research Research and Governance Support 2020
funds funding advocacy awareness costs costs Total
Note £ £ £ £ £ £ £
Staff costs 7 1,049,290 245,434 230,629 479,048 114,315 302,920 2,421,635
Other staffing costs 24,653 3,018 9,488 46,461 1,613 34,430 119,663
Office costs 85,908 9,696 13,532 29,083 1,302 24,621 164,142
Rent and premises 138,598 20,386 18,110 45,615 3,219 46,137 272,065
Depreciation — — — — — 31,612 31,612
Information technology costs 30,293 5,699 4,499 10,498 900 12,897 64,785
Direct fundraising costs
. Donations and appeals 180,921 — — — — — 180,921
. Third party fundraising 1,366 — — — — — 1,366
. One Walk 31,312 — — — — — 31,312
. Running and challenge
events 138,135 — — — — — 138,135
. Trading activities 6,755 — — — — — 6,755
. Events and other
fundraising activities 244,551 — — — — — 244,551
Subtotal direct fundraising
costs 603,039 — — — — — 603,039
Audit fees — — — — 11,712 — 11,712
Governance — — — — 5,974 — 5,974
Advocacy — 3,930 57,306 — — — 61,236
Support and awareness — — — 273,638 — — 273,638
Research grants –
unrestricted 5 — 521,772 — — — — 521,772
Research grants – restricted 5 — 1,348,219 — — — — 1,348,219
1,931,781 2,158,154 333,562 884,343 139,036 452,616 5,899,492
Support costs 238,530 54,679 51,243 108,164 — (452,616) —
Governance costs 73,272 16,796 15,741 33,226 (139,036) — —
Total expenditure 2020 2,243,583 2,229,629 400,547 1,025,733 — — 5,899,492
**----- End of picture text -----**
Notos to the financial statements 30 June 2021 5 Research grants 2021 2D20 PINICipal inV￿￿J£tor Restrfctsd Unrestri¢t•d Totsi Restrlcted Unresithxed Tctsi Unlvorsity ofEx•t•r Der￿ing the decline in enaoienous insulm 5e¢rdion In Type 1 dlabeies diagnosed after30 yearsofsit ¢ardlff Unl¥•rslty 0need￿ Strays to d￿Ner￿￿jE￿ specfftlm￿￿CtherapY Cardlfl Unlvorslty Clinl¢#l Trlals In the Type 1 Dkgbetes UK IMmnoth*rapy Consortium Bi19er. Smgrter. F89ter Cardiff Uniyetslty Th8 bel&2 scor8 and b8yond composit8 OUtcom8S mgasure$ of l$lfrt cellfunthon for u$9 ID ¢linK4 Inal$ ediGAI ReSe8reh Courtil INRCI PEG-Ba8ed HydrogetstsiPSC>D8rivod R898n8r￿we ThBrap1eSforD￿￿beteS IPI". Rouo Sanchol Unlvgr<y ol Camtyrldge Tr£ckin¢ otrigkf0rdiabEt￿n*phrtrP￿￿Y and tard￿¥89¢U12r dise£se In yOunJ PeO￿e typè I 118b￿&s ￿¢furt¢d iOth& AdDlT￿UdY Queen's Unwersity 8eh45t Novel lffl$1ghts onihe Link bgtwegn DIabg1￿ Retwpathy an Ihg Sp￿n￿clock The Unlveraity of Edlnburgh u￿￿9 Deep Leaming ￿ Retina Images lo Predict CDmplications and Therap8Utic r8spons@s In Type 1 Diab8t88 Unlversity orBrlstol UK TnalNet Clinical Cenler An#uS Jones 17.259 46,924 64.183 Colin Dayèn 2,000 Colln DAyAn 85,820 87.620 Colin Dayan 380,547 380,547 421.536 421.536 $4,625 54,628 13.tyJ8 13.906 David Dunger 34,e78 $4.876 65,579 75.995 Colhoun 186,301 75.wo 75.￿0 48.36$ 5B.782 Kath1￿￿ Gi1￿8p18 80,042 36,449 96,491 46,915 48.915 How d¢ Slow Progressors iotype 1 digb•teSrtyu￿te iheir auiolmmun* reswnse ? Klno's Colleotr London ACC *utyextension". T￿9 fun￿10￿ and C-peptide change Unlv•rslty ol Ex•t•r Improvgd, cosi effe¢tiw• pred￿10￿ oliyP• I diaWe$ In ewty lrfe usln9 coMblneJ wdl¢tl¢D models Klng's College London Expforing the ￿￿latIonal PDiential ￿the NPY Y4 recepknfor treatlllg Type 1 Diabetes Klnu's Coll8g8 London A HYptylyceM￿ Aworeness Re*crfatlon Prtyram tor people wmh type 1 dlèbeies and probkmauc hypoglyc*nla perS1*￿g ￿￿￿.9 College Lgndon amonizin9 In dini￿lIrIalSOf U*9k￿urDab Unlv•rEliy ol Ex8t8r Matk Peskm8 6,926 11.928 RICh¥d 136.723 12461 136A78 54.864 Ga￿n Bov￿ck 41.826 41,826 134,943 12441 134.699 StephanieAmi 18.125 20,872 20.872 Tlmothy Treg 136,163 146.344 9,170 PaulWPDiter 6.359 9.841 15.000 3,750 3.750 hypogly¢eml8 Uwrtweluldti Queen M4ty, Unlvershy Of Lond¢n Om￿al￿e post-translatianally madrfied Insulin as neoBpitDpe I typ8 I diab8t@s staging, pathog8né¥i¥ Ih9r8pwtic utilrty UnlvgrEliy ol Oxlord Human IsiÈtg For B2$1¢ Re9e8rth- Oxfoid JDRF Hum2n l$let Re#ource Centre Ahuva Nisslm 35.327 35.327 PaulJahnyon Unlversity of Brlstol JORF Irteinètlonal CWnKa siies- UK (Trtslneii College u￿Trg lleuroimaoino toundemandlhe rD￿ ofcagnrtions in r￿aring hypDgtycEmi* awarene85 In wth type 1 diabetes Impaired awarenpss of hypaglywn Quwn's Unlv8rslty 88lfa8t meswng ya6¢ukir stem Cells 10 modeland treat diabot retlnopothy Unlyerslty orDundee Restorin9 hypoglyc8mk? a￿9￿9$$1hTough d15habrtuati Unlvgr611y ol Oxlord Rokorthe ÈutoÈnti¢en tetr&spÈnin-7 in type 1 dIa￿te$ Unlvorslty of Ex•t•rand Hobrew Unfv8rs1ty of J8rusalB c8l1tumov￿1￿ patKpN$wth bng-standingiyp& 1 diab81*6 IBIRAXI PoltyBln9 30,730 30,735 95.842 95.842 Pratsk Ch(thh ReInh￿d Medina 33.498 55.LI18 Rory M¢CrirrYnon 4U.212 4Q.212 mCL￿h11 20.803 20.863 1,753 12.756 yUV￿ D( 24.WO 30,121 54.121 Juvenile Diabetes Research Foundation Limited 39 Notos to the financial statements 30 June 2021 Research grants Icontinuedl 2021 2020 Restricted Unrestricte Total ReslTKted UnresiriGted Total Investigator Unlv•rs1ty ol Edlnburgh Validation of Novd Candidate Biomstkers for Di￿betiC K￿TreY Di8ea¥e In LaTge CDhortS of PEDple wth Type 1 Di£bete5 University of Lincoln Phenotype and sKÈthliuty of the IsleiinflammatiDn In Type Hekn Coihoun 6,275 26.414 32,689 M￿381 Chti81 54,142 54,142 44.853 44,853 Unlverslty of Brfstol Aduiion$etType 1 Di8bete$. Slow Pwressots or L8le Starters? Univer6ity of Dundee Predictors of Early Stage tkdine in ￿dneY Function In Type 1 Diabetes King's College, London Comparison of Meo- and natural ewlope readivity as Il relates ID Disease Stage. Tcell rectuitmenl and Anno Long 47,890 47,890 78,87 78,87e Colhoun 26,414 17.318 43,732 Matk Peakma 32,447 32,447 Institute for Med Res, Unlv of Cambrfdge Tn¥lNet TranEcriptorniG Pipeline Cardiff University Do time￿I￿ay￿ependenl changes In re9ulalory T-￿IlS allerlheirability lo suppress the developmentofType 1 diabetes In NOD mice Eoln McKNin* 294,317 294317 James Pearson 15.DDO 15.000 Unlverslty of Exeter Killing the beta cell killers to slcw prwression prevent type 1 diabetes Unlverslty of Exeter Does Ittskè a IDt ol nerwe to regenets￿ pancyeallc beta cdls Matbn E1Ch￿nn 14,868 14858 Yu Hsu8n CardYan9 1S,DDO 15,000 Univorsity of Bri¥tol Kath￿en Ciik$pie 10,126 21,616 31,741 di¥b8t&s Infecbon r¥ie and effects on di¥beies JDRF T1D Fund 26U,8 268,Bt3 Unlverslty of Edlnburyh IConn•tt Immun• Ras•&rch aWArdl Pre¢i$ion type I Interferon biomarkers for the str811fi￿tI0Th ol aulolmmune dise2¥e University of Ex8tsr ml￿￿lation of brain fatty acid oxidation lo improve hypoglyraemia Gounler regUlat￿n Yainh* Crow 17,822 17,822 45.186 45.186 1,793,554 245,797 2,D40,351 1.348,219 521.772 1.869,991 Juvenile Diabetes Research Foundation Limited 40 Notos to the financial statements 30 June 2021 6 Net income {expenditurel before transfers This is staled after charging.. 2021 2020 Depreciation Directors, indemnity insurance Auditorfs remuneration lexcluding VATI Audit for current year Under accrual for previous year Operating lease rentals Property 31,599 541 31,612 541 10,585 9.800 1,912 158,048 1S1,508 7 Staff costs and numbers and remuneration of key management personnel Staff costs were as follows". 2021 2020 Salaries and wages Social security costs Pension contributions 1,982,337 193,352 112,272 2,287,961 2,115,109 203.995 102,531 2,421,635 The average weekly number of employees lon an average head count and a full lime equivalent basis) carying out JDRF'S activities was as follows.. Head count Head count FTE 2021 2020 FTE 2021 2020 R815ing funds Charitable activities Central support 24 23 27 25 22.2 21.2 25.8 23.5 10.3 56 63 52.0 59.6 The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, and the executive management team. The total remuneration (including taxable benefits and employer's pension conlributionsl of the key management personnel for the year was £431,701 12020 £404,603). During the year JDRF made non contractual severance payments of £3,67912020." £nill- These payments were approved by the Iruslees for payment. 2021 2020 Employee between £90k & £100k Employee between £80k & £90k Employee between £70k & £80k Employee between £60k & £70k The pension contributions paid during the year for these employees lotalled £43,831 12020 - £34,785). Juvenile Diabetes Research Foundation Limited 41 Notos to the financial statements 30 June 2021 8 Taxation The charity is exempl from Corporation tsx as all ils income is charitable and is applied for charitable purposes. The charity's trading subsidiary JDRF Trading Limited gift aids available profits to the charity. 9 Tanglble flxed assets Leasehold improvemen15 Computer equipment Fixtures and fittings Totsl Cost At 1 Juty 2020 Additions In the year At 30 June 2021 108,381 142,516 12,787 155,3Q3 7,176 258,073 12,787 270.860 108,381 7,176 Depreclatlon At 1 Juty 2020 Charge for the year At 30 June 2021 64.056 11.081 75.137 70.951 20,518 91.469 7.176 142,183 31,599 173,782 7.176 Net book value At 30 June 2021 33.244 44.325 63.834 71.565 97,078 115,890 At 30 June 2020 10 Investmgnts 2021 2020 Investment in unquoted subsidiary undertaking at cost 10,001 10.001 Juvenile Diabetes Research Foundation Limited 42 Notos to the financial statements 30 June 2021 11 Subsidiary undertaking The charitable company owns the whole of the issued ordinary share capital of JDRF Trading Limited, a company registered in England on 17 De￿mber 2007. The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the statement of financial activities. Available profits are gift aided to the charitable company. A summary of the results of the subsidiary Is shown below.. 2021 2020 Tumover Cost of sales Gross profit 282.097 208.204 282,097 208,204 Adrninislrative expenses Operating profit 153,9791 228.118 150.8651 157,339 Taxation Profit on ordinary activities after taxation 228,118 157,339 Gift aid distribution to parent undertaking Movement in retsined earnings 1228,1181 1157,3391 The aggregate of the assets, liabilities and funds was.. 2021 2020 Assets Liabilities Funds 327,313 1317,3121 10,001 202,772 1192.7711 10,001 12 Parent undertaking The parent undertaking's gross income and the ￿SUItS for the year are disclosed as follows". 2021 2020 Gross income Results for the year 6,093,549 615,385 5,83e,549 112.0781 13 Debtors Group 2021 Charty 2021 2020 2020 Trad& debto Other debtors Amounts due from subsidiary Prepayments Accrued Income 72,394 101.180 6,533 9.250 66,500 6,533 70,104 160,792 139,545 443,475 159.790 222,209 129.044 520.293 222,209 129,044 423.647 160.792 142,045 410,551 Juvenile Diabetes Research Foundation Limited 43 Notos to the financial statements 30 June 2021 14 Credltors: amounts due wlthln one year Group 2021 Charty 2021 2020 2020 Trade creditors Taxation and sotial 5eGurity Other creditors Rent free benefit over lea$e period Deferred income Accru8d cost8 55.010 65h37 28,249 19,836 144,750 124,260 437.542 5,555 46.869 19,722 25.185 122,642 90,012 309,986 55.010 4B,665 28.249 19.83$ 4,000 124.260 280.020 5,555 46,845 19,722 25,185 90,012 187,319 Included in deferred income are amounts re￿iVed in advan￿ for events and sponsorship as set out below". Group 2021 Charty 2021 2020 2020 Brought fO￿ard as at 1 Juty Additional inGome deferred in year Brought fO￿ard funds rekased in year Carried fotward as at 31 June 122.642 144,750 1122,6421 144,750 85,925 122.642 185,9251 122,642 800 4.000 18001 4,000 15 Analysis of net assets between funds Totsl funds 2021 Total funds 2020 Re8tr1ctod Unrestrfcted funds funds Restricted Unrestricted funds funds Group Tangible fixed a55els N81 curr8nl a888ts Nel 8s5els at 30 June 97,078 406.757 1,720,145 406.757 1,817,223 97,078 2.126.902 2.223.980 115.891 115.891 869.432 1.264.588 985.322 1.380.478 395,156 395,156 Totsl funds 2021 Total funds 2020 Restrlcted Unrestrfcted funds funds Restricted Unrestricted funds funds Chatlty Tangible fixed assets Investments Nel current a$5els Nel 855els 81 30 June 97,078 10,001 406,757 1,710,144 406,757 1,617,223 97,078 10,001 2,116,901 2,223,980 115.891 115.691 10.001 10.001 859.430 1.254.586 985.322 1.380.478 395,156 395.156 Juvenile Diabetes Research Foundation Limited 44 |_Restricted funds_
_Research funding_
_Steve Morgan Foundation_
_Support and awareness_
_Total restricted funds_
_Unrestricted funds_
_General funds_
_Total funds_|_At 1_
_July_
_2019_
_£_
_114,818_
_(30,965)_
_33,432_
_117,286_
_1,117,930_|_Income_
_£_|_Expenditure_
_£_
_(408,113)_
_(940,105)_
_(85,963)_
_(1,434,182)_
_(4,465,310)_|_At 30_
_June_
_2020_
_£_| |---|---|---|---|---| |||_631,921_
_1,000,000_
_80,131_
_1,712,052_
_4,332,702_||_338,626_
_28,930_
_27,600_
_395,156_
_985,322_| ||_1,235,216_|_6,044,754_|_(5,899,492)_|_1,380,478_| ## _**Purpose of restricted funds**_ Notos to the financial statements 30 June 2021 18 Related party transactions Trustee expenses for the year tolalled £nil12020 £nill and charitable donations received from trustees lotalled £38,57512020 - £73,722). There were no other transactions with related parties which required disclosure during the year12020- none). Juvenile Diabetes Research Foundation Limited 46